MedTrace Logo

Gene Therapy for ACM Due to a PKP2 Pathogenic Variant

NCT06109181 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-11-12

No results posted yet for this study

Summary

This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM

Conditions

  • Arrhythmogenic Cardiomyopathy
  • PKP2-ACM
  • PKP2-ARVC

Interventions

GENETIC

LX2020

LX2020 is an adeno-associated viral vector encoding the human Plakophilin-2 (PKP2) gene (AAVrh.10hPKP2)

Sponsors & Collaborators

  • Lexeo Therapeutics

    lead INDUSTRY

Principal Investigators

  • LEXEO Clinical Trials · Lexeo Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-29
Primary Completion
2026-12-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06109181 on ClinicalTrials.gov